Perioperative Buprenorphine: Continue, Reduce, or Hold for Elective Surgery
A patient in stable recovery from opioid use disorder needs a routine gallbladder operation. The disagreement isn't whether his recovery matters — everyone agrees it does — it's whether protecting it means leaving his daily buprenorphine exactly as it is, or making room around it for the pain a real operation will cause.
R.T., a 41-year-old man, has been sober from illicit opioids for four years, a fact he brings up before almost anything else about himself — he sponsors two people in his recovery program now, works full-time installing HVAC systems, and has rebuilt a relationship with his teenage daughter that he says he thought he'd lost for good. He has taken buprenorphine-naloxone 16mg/4mg daily for OUD maintenance since starting recovery, prescribed and monitored through the same clinic the entire time, with no missed doses documented in over two years. Two weeks of worsening right upper quadrant pain after fatty meals, followed by an ultrasound confirming symptomatic gallstones, has put him on the schedule for a laparoscopic cholecystectomy — his first surgery since starting buprenorphine, and the first time anyone on his care team has had to actually decide what happens to his daily dose around an operation rather than just refill it.
The old teaching — stop buprenorphine three to five days before surgery to "make room" for full-agonist analgesia — has been reversed by the same body of evidence that produced it: the 2021 multisociety panel convened by ASRA with ASA, ASHP, AAPM and ASAM — Kohan and colleagues — which recommends against routinely discontinuing buprenorphine perioperatively and then goes one step further than most clinicians remember: it recommends avoiding a perioperative taper as well, at grade B, on the reasoning that receptor-availability studies and case reports show adequate analgesia is achievable even at high buprenorphine doses. The panel's acknowledgment that practice still varies is scoped to patients above 16mg and to procedures with high anticipated postoperative pain. R.T. is at 16mg exactly, facing a same-day laparoscopic operation whose pain most patients clear within days — which places him inside the group the panel tells you not to taper, not in the band where it concedes the question is open. What that leaves genuinely contested is not whether the recommendation covers him, but how much a grade-B recommendation built on receptor-availability data and case reports should outweigh a bedside anesthesiologist's own experience of titrating a rescue agonist against a receptor that is already occupied.
Pre-op clinic, three weeks out
Continue the 16mg unchanged. Buprenorphine's own analgesic activity is real, not theoretical — at ceiling it still contributes meaningful pain relief, and a full agonist added on top for breakthrough pain works, it just sometimes needs higher doses than a buprenorphine-naive patient would. What it doesn't survive is interruption. I've watched a stable patient relapse after a well-intentioned "just for the surgery" taper more than once, and four years of remission is not a margin I'm willing to spend on a moderate-pain operation Kohan's 2021 multisociety panel explicitly names as a continue-through case.
If this were a major open abdominal case with days of severe expected pain, I'd be having a different conversation — that's the setting where the panel itself admits practice still varies, and I'm not pretending that variation doesn't exist.
I'm not proposing interruption either — I agree that ship has sailed and shouldn't come back. But "continue unchanged" undersells how hard 16mg of high-affinity partial agonist fights a rescue full agonist at the receptor. I've stood at the bedside titrating hydromorphone against a buprenorphine level that's occupying most of the available receptor, and the analgesic return per milligram is genuinely blunted — not zero, but real. Dropping him to 8mg/2mg preoperatively keeps him fully protected from withdrawal while giving a rescue agent more actual room to work if he needs it Tuesday night.
I'll be straight that the panel is against me on this: it recommends avoiding a perioperative taper, not just avoiding discontinuation, so I'm arguing against a graded recommendation rather than filling a gap in one. What I'd press on is what that grade B rests on — receptor-availability studies and case reports, in a panel that concedes practice still varies — and whether that's enough to settle what I should do at eight o'clock Tuesday evening.
You're both right about something the other one isn't contesting: neither position touches whether he actually gets a real multimodal plan. A laparoscopic cholecystectomy's expected pain is modest enough that scheduled acetaminophen, ketorolac unless a contraindication turns up, and a TAP block at the end of the case will do most of the real work either way — and the gap between "16mg" and "8mg" for a full-agonist rescue matters far less if that plan is actually built and running before he wakes up than if it isn't.
Waiting to decide the buprenorphine dose "once we see how he does" isn't a third option — someone has to write the pre-op order today, and today's order is what actually determines his receptor occupancy Tuesday morning, not a plan to reassess later.
Agreed: buprenorphine-naloxone continued at his home 16mg/4mg, neither stopped nor tapered; scheduled acetaminophen and ketorolac; bilateral TAP block at closure; hydromorphone available for breakthrough pain at above-standard starting doses, titrated at the bedside rather than pre-committed to a number. His addiction medicine clinic notified and looped in for same-day post-op follow-up.
Not agreed, and carried forward rather than smoothed over: whether the anesthesiologist's receptor-occupancy argument should have carried the day anyway. His position is that a grade-B recommendation resting on receptor-availability studies and case reports is a thinner basis than its wording suggests, and that the panel wrote it without a patient at 8pm in front of it. The addiction medicine specialist's answer is that a thin recommendation is still the only one there is, and that the burden sits on whoever wants to taper. Neither conceded; the plan follows the panel because nobody could produce evidence strong enough to justify departing from it, not because the objection was answered.